Oric Pharmaceuticals provides operational highlights for 2025

ORIC Pharmaceuticals (ORIC) announced operational highlights for 2025 and anticipated upcoming milestones. Key highlights includes: Announced rinzimetostat Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors; Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose; Raised $244 million from top-tier healthcare specialist funds; Cash and investments of $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout for rinzimetostat Phase 3 study; Expect to report multiple clinical data readouts for rinzimetostat and enozertinib in 2026, ahead of potential initiation of multiple registrational trials